- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01902823
Effect of Cancer Nurse Navigators on Patient Outcomes
December 12, 2019 updated by: University of Wisconsin, Madison
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
There is widespread anecdotal evidence that Cancer Nurse Navigators (CNNs) are highly valued by cancer patients, but no studies have evaluated the effects of CNNs on important patient-reported outcomes or indicators of quality of care. This study has two aims:
- To assess the feasibility of studying the impact of Aurora CNN Program.
- To pilot test the effects of CNN services on patient-reported outcomes and indicators of quality of care.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
- Aurora St. Luke's Hospital
-
West Allis, Wisconsin, United States
- Aurora West Allis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult (18 years of age or older)
- Treated at Aurora St. Luke's or West Allis Medical Center
- New or recurrent dx of lung, prostate, colorectal or breast cancer -
Exclusion Criteria:
- Previously received CNN services at an Aurora treatment facility
- Unable to read/write in English
- Living in a nursing home/long term care facility
- Not capable of completing study questionnaires -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No Nurse Navigator Services
|
|
Experimental: Services from a Nurse Navigator
|
Services from a Nurse Navigator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Satisfaction with Care
Time Frame: Change from baseline, to 3 months to 6 months
|
Change from baseline, to 3 months to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ED/Urgent care visits
Time Frame: Baseline, 3 months, 6 months
|
Baseline, 3 months, 6 months
|
|
Quality of Life
Time Frame: Baseline, 3 months, 6 months
|
The Functional Assessment Cancer Therapy - General (FACT-G) assesses quality of life.
|
Baseline, 3 months, 6 months
|
Distressed mood
Time Frame: Baseline, 3 months, 6 months
|
The National Comprehensive Cancer Network Distress Thermometer assesses level of distress.
|
Baseline, 3 months, 6 months
|
Symptom Distress
Time Frame: Baseline, 3 months, 6 months
|
The Memorial Symptom Assessment Scale measures 32 common physical and psychological cancer-related symptoms.
|
Baseline, 3 months, 6 months
|
The Inventory of Recent Life Experiences for Cancer Patients
Time Frame: Baseline, 3 months, 6 months
|
This instrument measures 30 cancer-related irritants (hassles) commonly experienced by persons with cancer.
|
Baseline, 3 months, 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kristine Kwekkeboom, PhD, RN, University of Wisconsin, Madison
- Principal Investigator: Sandra E Ward, PhD, RN, Uniuversity of Wisconsin Madison
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
May 1, 2012
Study Registration Dates
First Submitted
November 29, 2011
First Submitted That Met QC Criteria
July 15, 2013
First Posted (Estimate)
July 18, 2013
Study Record Updates
Last Update Posted (Actual)
December 13, 2019
Last Update Submitted That Met QC Criteria
December 12, 2019
Last Verified
November 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-86E
- A545000 (Other Identifier: UW Madison)
- NUR/FACULTY AFFAIRS/ADMIN (Other Identifier: UW Madison)
- OS11336 (Other Identifier: UW Carbone Cancer Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on Services from a Nurse Navigator
-
Odense University HospitalCompleted
-
Medical University of South CarolinaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompleted
-
Cancer Care OntarioCanadian Institutes of Health Research (CIHR)Completed
-
National Institute for Tuberculosis and Lung Diseases...CompletedPain, Postoperative | Surgery, ThoracicPoland
-
Denver Health and Hospital AuthorityUniversity of Colorado, Denver; National Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Wake Forest University Health SciencesDuke UniversityCompletedAdvance Care PlanningUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownBreast Cancer | Surgery | Skin Cancer | AmbulatoryFrance
-
Taipei Medical UniversityCompletedNeoplasms | Nurse-Patient Relations | Psychiatric DisorderTaiwan
-
Boston Medical CenterBU Clinical and Translational Science InstituteCompleted